Microbiome and Genetic Factors in the Pathogenesis of Liver Diseases

• Published in: Gastroenterology Insights
• Main Authors: Dimitrina Miteva, Monika Peshevska-Sekulovska, Violeta Snegarova, Milena Peruhova, Georgi H. Vasilev, Georgi V. Vasilev, Metodija Sekulovski, Snezhina Lazova, Milena Gulinac, Latchezar Tomov, Antoaneta Mihova, Tsvetelina Velikova
• Format: Article
• Language: English
• Published: MDPI AG 2023-11-01
• Subjects: genomics; liver disease; microbiome; gut microbiota; NAFLD; liver cirrhosis
• Online Access: https://www.mdpi.com/2036-7422/14/4/41

Our genetic background has not changed over the past century, but chronic diseases are on the rise globally. In addition to the genetic component, among the critical factors for many diseases are inhabitants of our intestines (gut microbiota) as a crucial environmental factor. Dysbiosis has been described in liver diseases with different etiologies like non-alcoholic fatty liver disease (NAFLD), alcohol-related liver disease (ALD), viral hepatitis, autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), cirrhosis, hepatocellular carcinoma (HCC). On the other hand, new technologies have increased our understanding of liver disease genetics and treatment options. Genome-wide association studies (GWAS) identify unknown genetic risk factors, positional cloning of unknown genes associated with different diseases, gene tests for single nucleotide variations (SNVs), and next-generation sequencing (NGS) of selected genes or the complete genome. NGS also allowed studying the microbiome and its role in various liver diseases has begun. These genes have proven their effect on microbiome composition in host genome–microbiome association studies. We focus on altering the intestinal microbiota, and supplementing some bacterial metabolites could be considered a potential therapeutic strategy. The literature data promote probiotics/synbiotics role in reducing proinflammatory cytokines such as TNF-α and the interleukins (IL-1, IL-6, IL-8), therefore improving transaminase levels, hepatic steatosis, and NAFLD activity score. However, even though microbial therapy appears to be risk-free, evaluating side effects related to probiotics or synbiotics is imperative. In addition, safety profiles for long-term usage should be researched. Thus, this review focuses on the human microbiome and liver diseases, recent GWASs on liver disease, the gut-liver axis, and the associations with the microbiome and microbiome during/after liver disease therapy.